Bronchiectasis Section
-
Airway clearance pharmacotherapy: Past, present, and future
The central question in non-CF bronchiectasis is no longer whether mucoactives work but for whom, under what circumstances, and at what cost in treatment burden.
-
Airway crossroads: The overlap of bronchiectasis and obstructive lung disease
Bronchiectasis frequently coexists with asthma or COPD, forming an overlap phenotype that’s increasingly recognized but often overlooked.
-
Strengthening more than just airways
Emerging research reveals that nutrition and exercise are two powerful yet underutilized tools in managing bronchiectasis.
-
Bronchiectasis: A call to action
Bronchiectasis is an extremely heterogeneous airways disease, making it difficult to study. For years, the noncystic fibrosis (CF) bronchiectasis community has been trying to organize to provide better care for more than half a million adults with bronchiectasis in the United States. Internationally, the Europeans created the European Bronchiectasis Registry, which has been a powerful…
-
Eradicating uncertainty: A review of Pseudomonas aeruginosa eradication in bronchiectasis
Bronchiectasis patients have dilated airways that are often colonized with bacteria, resulting in a vicious cycle of airway inflammation and progressive dilation. Pseudomonas aeruginosa is a frequent airway colonizer and is associated with increased morbidity and mortality in cystic fibrosis (CF) and noncystic fibrosis bronchiectasis (NCFB).1 Both CF and NCFB guidelines recommend eradication of P.…
